Chorvinsky Elizabeth, Nino Gustavo, Salka Kyle, Gaviria Susana, Gutierrez Maria J, Pillai Dinesh K
Division of Pediatric Pulmonary and Sleep Medicine, Children's National Medical Center, George Washington University, Washington, DC, United States.
Division of Pediatric Allergy, Immunology and Rheumatology, Johns Hopkins University, Baltimore, MD, United States.
Front Pediatr. 2022 Sep 29;10:971073. doi: 10.3389/fped.2022.971073. eCollection 2022.
Thymic stromal lymphopoietin (TSLP) is increasingly recognized as a key molecule in asthma pathogenesis and as a promising therapeutic target in adults. In contrast, in asthmatic children the clinical relevance of TSLP secretion in the lower airways has been remarkably understudied. We tested the hypothesis that pulmonary TSLP levels in asthmatic children correlate with clinical severity, airway inflammation and lower airway obstruction.
Bronchoalveolar lavage (BAL) samples and relevant clinical data were collected from asthmatic children undergoing clinically indicated bronchoscopy at Children's National Hospital in Washington D.C. Protein levels of TSLP, IL-5, IL-1β, and IL-33 were quantified in BAL at baseline and correlated with individual severity and clinical features including spirometry, serum IgE and eosinophils, BAL neutrophil and eosinophil counts.
We enrolled a total of 35 asthmatic children (median age: 9 years). Pediatric subjects with severe asthma had greater TSLP BAL levels at baseline relative to mild or moderate asthmatic subjects ( = 0.016). Asthmatic children with the highest TSLP levels (>75th percentile) had higher IL-5 and IL-1β BAL levels and greater lower airway obstruction (lower FEV1/FVC ratios).
Our study demonstrates for the first time that higher pulmonary TSLP levels obtained at baseline are linked to asthma disease severity in a subset of children. These data indicate that TSLP may play a key role in the pathogenesis of pediatric asthma and thus provide initial support to investigate the potential use of anti-TSLP biologics to treat severe uncontrolled asthmatic children.
胸腺基质淋巴细胞生成素(TSLP)日益被认为是哮喘发病机制中的关键分子,也是成人哮喘颇具前景的治疗靶点。相比之下,哮喘儿童下呼吸道TSLP分泌的临床相关性研究明显不足。我们检验了以下假设:哮喘儿童的肺部TSLP水平与临床严重程度、气道炎症及下气道阻塞相关。
从华盛顿特区儿童国家医院接受临床指征支气管镜检查的哮喘儿童中收集支气管肺泡灌洗(BAL)样本及相关临床数据。在基线时对BAL中TSLP、IL-5、IL-1β和IL-33的蛋白水平进行定量,并与个体严重程度及临床特征相关联,这些特征包括肺功能测定、血清IgE和嗜酸性粒细胞、BAL中性粒细胞和嗜酸性粒细胞计数。
我们共纳入35名哮喘儿童(中位年龄:9岁)。与轻度或中度哮喘患儿相比,重度哮喘患儿在基线时BAL中的TSLP水平更高(P = 0.016)。TSLP水平最高(>第75百分位数)的哮喘儿童,其BAL中IL-5和IL-1β水平更高,下气道阻塞更严重(FEV1/FVC比值更低)。
我们的研究首次表明,基线时较高的肺部TSLP水平与部分儿童的哮喘疾病严重程度相关。这些数据表明TSLP可能在儿童哮喘发病机制中起关键作用,从而为研究抗TSLP生物制剂治疗严重难治性哮喘儿童的潜在用途提供了初步支持。